

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT6623844

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
SHI-YUAN CHENG	03/13/2021
BO HU	03/13/2021
TIANZHI HUANG	03/14/2021
RECEIVING PARTY DATA	
Name:	NORTHWESTERN UNIVERSITY
Street Address:	633 CLARK STREET
City:	EVANSTON
State/Country:	ILLINOIS
Postal Code:	60208
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	17017351
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Email:	timothy.storniolo@quarles.com, pat-dept@quarles.com
Correspondent Name:	QUARLES & BRADY LLP
Address Line 1:	33 EAST MAIN STREET
Address Line 2:	SUITE 900
Address Line 4:	MADISON, WISCONSIN 53703
ATTORNEY DOCKET NUMBER:	702581.01829
NAME OF SUBMITTER:	TIMOTHY STORNILOLO
SIGNATURE:	/Timothy Storniolo/
DATE SIGNED:	03/26/2021
Total Attachments: 4	
source=67616105_1#page1.tif	
source=67616105_1#page2.tif	
source=67616105_1#page3.tif	
source=67616105_1#page4.tif	

ASSIGNMENT

Application Serial No: 17/017,351

Filing Date: 9/10/2020

Inventors: Shi-Yuan Cheng, Bo Hu, Tianzhi Huang

Title of Patent Application: METHODS FOR ENHANCING CYTOTOXIC CANCER THERAPY THROUGH INHIBITION OF ATG4B

For good and valuable consideration, the receipt and sufficiency of which are hereby agreed, each of the undersigned hereby assigns to **Northwestern University**, an Illinois not-for-profit corporation, having a place of business at 633 Clark Street, Evanston, Illinois 60208 and its successors and assigns (“Assignee”) the entire right, title and interest in and to the inventions of such undersigned disclosed in the application listed above, and in any and all other applications anywhere in the world which the undersigned may file and/or be named as an inventor of, solely or jointly, on said inventions, in any and all patents which may be obtained on any of said applications and in any and all reissues, reexaminations, supplemental examinations, inter partes reviews, oppositions, post-grant reviews, supplementary protection certificates and/or extensions thereof, including without limitation, the right to bring suit and to claim and retain all damages and/or seek other remedies for the past, present and future infringement of any of the foregoing, the right of priority, including without limitation to claim priority benefit of or to said patent applications, and request the Commissioner for Patents in the United States and similar authorities outside the United States to issue said patents to and in the name of the Assignee.

Each of the undersigned states that the application listed above is or was made or authorized to be made by him or her. Each of the undersigned believes himself or herself to be the original inventor or a joint inventor with another undersigned of a claimed invention in the application listed above. Each of the undersigned acknowledges that any willful false statement made by him or her in this paragraph is punishable under 18 U.S.C. §1001 by fine or imprisonment of not more than five years, or both.

Except in favor of Assignee, each of the undersigned warrants that: (i) he or she is the owner of all its rights, titles and interests herein assigned and has the right to make this unconditional and irrevocable assignment to Assignee without obtaining any approval or permission of a third party; and (ii) there are no outstanding encumbrances, liens, prior assignments, licenses, or other obligations or restrictions on the rights, titles and interests herein assigned.

Upon the request of Assignee and at no expense to the undersigned, each of the undersigned hereby agrees to execute any and all applications on said inventions, including without limitation for the reissue, reexamination, supplementary protection certificate or extension thereof and any oath, declaration or

affidavit relating thereto that said Assignee may deem necessary or expedient, and to cooperate to the best of the ability of the undersigned with and perform any and all affirmative acts requested by Assignee to prepare, file, prosecute, maintain, defend, enforce and vest in Assignee the rights, titles and interests assigned herein, including without limitation, preparing and executing statements and giving and producing evidence in support thereof, whereby said rights, titles and interests will be held and enjoyed by said Assignee to the full end of the term for which said patents may be granted as fully and entirely as the same would have been held and enjoyed by the undersigned if this assignment had not been made.

(continued on next page)

Application Serial No: 17/017,351

Filing Date: 9/10/2020

Inventors: Shi-Yuan Cheng, Bo Hu, Tianzhi Huang


Title of Patent Application: METHODS FOR ENHANCING CYTOTOXIC CANCER THERAPY THROUGH INHIBITION OF ATG4B

Undersigned (ASSIGNORS):


Inventor Name: **Shi-Yuan Cheng**

3/13/21
DATE

Please sign and date in blue or black ink.


Inventor Name: **Bo Hu**

3/13/21
DATE

Please sign and date in blue or black ink.


Inventor Name: **Tianzhi Huang**

3/14/21
DATE

Please sign and date in blue or black ink.

(continued on next page)

Application Serial No: 17/017,351


Filing Date: 9/10/2020

Inventors: Shi-Yuan Cheng, Bo Hu, Tianzhi Huang

Title of Patent Application: METHODS FOR ENHANCING CYTOTOXIC CANCER THERAPY THROUGH INHIBITION OF ATG4B

ASSIGNEE ACCEPTANCE: Northwestern University:

On behalf of Northwestern University, Assignee, the authorized signatory below, hereby confirms Assignee's acceptance of all rights, privileges, titles and interests conveyed by this Assignment.

Authorized Signature:  Date: 03/24/2021

Printed Name: Heather Fletcher, Manager of INVO Docketing & Compliance, or
Amanda Belle Culbertson, Intellectual Property Docketing Coordinator, or
Dragos Visan, Director of Finance & Technology

Department: Innovation and New Ventures Office (INVO)